Jazz Pharmaceuticals acquires Actio Biosciences for rare epilepsy portfolio, and the company's investigational drug secures multiple FDA designations.
2 reports, 1 independent
Updated Sep 18
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Jazz Pharmaceuticals acquires Actio Biosciences for rare epilepsy portfolio, and the company's investigational drug secures multiple FDA designations.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Jazz Pharmaceuticals received FDA approval for a drug following positive clinical trial results.Sub-event
Jazz Pharmaceuticals acquires Actio Biosciences and secures multiple FDA designations for rare epilepsy portfolio.1 source
Keep exploring
The entities involved
-
Jazz Pharmaceuticals
Irish tax-registered pharmaceutical corporation
- FDA